Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 7/20 | 0.56 |
| ▸ | KIF11 | P52732 | 2/20 | 0.48 |
| ▸ | HRH2 | P25021 | 4/20 | 0.40 |
| ▸ | HRH1 | P35367 | 4/20 | 0.40 |
| ▸ | MMP2 | P08253 | 2/20 | 0.39 |
| ▸ | MMP3 | P08254 | 3/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.37 |
| ▸ | MMP1 | P03956 | 1/20 | 0.37 |
| ▸ | MMP9 | P14780 | 1/20 | 0.37 |
| ▸ | MMP13 | P45452 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1714334 | 0.88 | HRH3 (0.43) | HRH3 | |
| SCHEMBL9062436 | 0.85 | HRH3 (0.55) | HRH3KIF11HDAC1HDAC2 | |
| SCHEMBL7223288 | 0.84 | MRGPRX4 (0.42) | HRH3HRH2HRH1MMP2MMP3 | |
| SCHEMBL6847271 | 0.84 | HRH3 (0.55) | HRH3KIF11HRH2HRH1MMP2 | |
| SCHEMBL7226578 | 0.82 | HRH3 (0.42) | HRH3HRH2HRH1MMP2MMP3 | |
| SCHEMBL7220649 | 0.82 | HRH3 (0.40) | HRH3HRH2HRH1MMP2MMP3 | |
| SCHEMBL7222806 | 0.81 | KIT (0.46) | HRH3HRH2HRH1 | |
| SCHEMBL25040867 | 0.81 | HRH3 (0.49) | HRH3KIF11MMP2MMP3HDAC1 | |
| SCHEMBL7228230 | 0.79 | HRH3 (0.48) | HRH3KIF11HRH2HRH1MMP2 | |
| SCHEMBL25040490 | 0.79 | HRH3 (0.50) | HRH3KIF11MMP2MMP3HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6620839-B2 | 1,3-disubstituted and 1,3,3-trisubstituted pyrrolidines as histamine-3 receptor ligands and their therapeutic applications | ABBOTT LABORATORIES | 2003-09-16 | — | — | US | disclosed |
| US-20020137931-A1 | 1,3-disubstituted and 1,3,3-trisubstituted pyrrolidines as histamine-3 receptor ligands and their therapeutic applications | ABBVIE INC. | 2002-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020137931-A1 | 1,3-disubstituted and 1,3,3-trisubstituted pyrrolidines as histamine-3 receptor ligands and their therapeutic applications | HRH3, HRH4, HRH1 | HRH3 1/4885KIF11 4688/4885HRH2 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.